Literature DB >> 35907969

Anti-müllerian hormone as a predictor for live birth among women undergoing IVF/ICSI in different age groups: an update of systematic review and meta-analysis.

Ni-Jie Li1, Qing-Yun Yao1, Xiao-Qiong Yuan1, Yong Huang1, Yu-Feng Li2.   

Abstract

PURPOSE: To update the evidence of anti-müllerian hormone (AMH) as predictive factors for live birth outcome in women undergoing assisted conception and discover the modulating effect of age.
METHODS: PubMed, Embase, Medline, and Web of Science were searched for studies published until June 2021. We included studies that measured serum AMH levels and reported the subsequent live birth outcomes. Random effects models and hierarchical summary receiver operating characteristics (HSROC) models were used. The QUADAS-2 checklist was employed to assess the quality of the included studies.
RESULTS: We included 27 studies (27,029 women) investigating the relationship between AMH and live birth outcome after assisted conception. The diagnostic odds ratios (DOR) from random effects models were ruled out due to high heterogeneity. Our findings suggested that AMH was associated with live birth. The DOR was 2.21 (95% CI 1.89-2.59), and 2.49 (95% CI 1.26-4.91) for studies on women with unspecified ovarian reserve and women with low ovarian reserve, respectively. The DOR of those with advanced ages was 2.50 (95% CI 1.87-2.60). For younger women, the DOR was 1.41 (95% CI 0.99-2.02). HSROCs showed that AMH had no predictive ability towards live birth in women with diminished ovarian reserve or younger age. Exclusion of Chinese cohorts lowered the heterogeneity.
CONCLUSIONS: This study revealed that AMH had better prediction for live birth in advanced-age women. AMH may have implicative predictive value for assisted conception counseling of couples of advanced ages.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Age; Anti–müllerian hormone; Diagnostic odds ratio; IVF; Live birth

Year:  2022        PMID: 35907969     DOI: 10.1007/s00404-022-06683-1

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.493


  75 in total

1.  The association between anti-Müllerian hormone and IVF pregnancy outcomes is influenced by age.

Authors:  Jeff G Wang; Nataki C Douglas; Gary S Nakhuda; Janet M Choi; Susanna J Park; Melvin H Thornton; Michael M Guarnaccia; Mark V Sauer
Journal:  Reprod Biomed Online       Date:  2010-11-01       Impact factor: 3.828

Review 2.  Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis.

Authors:  Reshef Tal; Oded Tal; Benjamin J Seifer; David B Seifer
Journal:  Fertil Steril       Date:  2014-10-24       Impact factor: 7.329

3.  Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology?

Authors:  S Muttukrishna; H McGarrigle; R Wakim; I Khadum; D M Ranieri; P Serhal
Journal:  BJOG       Date:  2005-10       Impact factor: 6.531

4.  Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells.

Authors:  E Rajpert-De Meyts; N Jørgensen; N Graem; J Müller; R L Cate; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1999-10       Impact factor: 5.958

5.  Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients?

Authors:  Shanthi Muttukrishna; Harris Suharjono; Hugh McGarrigle; Muttukrishna Sathanandan
Journal:  BJOG       Date:  2004-11       Impact factor: 6.531

6.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  BMJ       Date:  2009-07-21

Review 7.  Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance.

Authors:  David B Seifer; David T Maclaughlin
Journal:  Fertil Steril       Date:  2007-06-07       Impact factor: 7.329

Review 8.  Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).

Authors:  A La Marca; G Sighinolfi; D Radi; C Argento; E Baraldi; A Carducci Artenisio; G Stabile; A Volpe
Journal:  Hum Reprod Update       Date:  2009-09-30       Impact factor: 15.610

Review 9.  Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high?

Authors:  Laura Pellatt; Suman Rice; Helen D Mason
Journal:  Reproduction       Date:  2010-03-05       Impact factor: 3.906

Review 10.  The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature.

Authors:  Stamatina Iliodromiti; Thomas W Kelsey; Olivia Wu; Richard A Anderson; Scott M Nelson
Journal:  Hum Reprod Update       Date:  2014-02-13       Impact factor: 15.610

View more
  1 in total

Review 1.  Circular RNAs as novel biomarkers in triple-negative breast cancer: a systematic review.

Authors:  Zahra Foruzandeh; Davood Ghavi Dorabadi; Farzaneh Sadeghi; Fatemeh Zeinali-Sehrig; Mohammad Zaefizadeh; Yazdan Rahmati; Mohammad Reza Alivand
Journal:  Mol Biol Rep       Date:  2022-05-10       Impact factor: 2.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.